{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:15:10Z","timestamp":1792080910783,"version":"4.4.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The mTOR inhibitor Sirolimus was shown to improve symptoms in patients with slow-flow vascular malformations, but long-term continuous use is limited by cumulative toxicity. A personalized approach with intermittent regimens may offer similar efficacy with fewer adverse effects (AE). This retrospective analysis evaluated the effectiveness and safety of individualized sirolimus strategies in patients who experienced symptom recurrence after completing the 2-year course in the VASE phase III trial. All patients initially resumed continuous sirolimus for 3\u2009months, then transitioned to one personalized regimen based on their pain profiles: intermittent sirolimus 5\u2009days-ON\/2\u2009days-OFF (Group A), hybrid intermittent plus on-demand (Group B), or fully on-demand administration triggered by pain or known stressors (Group C).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty adults were included (Group A:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913; Group B:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096; Group C:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911). Across all groups, intermittent, hybrid or on-demand sirolimus maintained pain control comparable to continuous administration, significantly reducing pain intensity, crisis frequency, and crisis duration from baseline. AEs decreased from 73\u201385% during continuous therapy to 9\u201333% with intermittent\/on-demand regimens, with no reported grade \u22653 event.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Personalized intermittent sirolimus regimens may effectively control symptoms and substantially reduce toxicity in patients with vascular malformations. This strategy supports individualized, long-term therapy and merits prospective validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration.<\/jats:title>\n                    <jats:p>NCT02638389 and EudraCT 2015-001703-32<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04151-y","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T03:56:57Z","timestamp":1765339017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort"],"prefix":"10.1186","volume":"21","author":[{"given":"Emmanuel","family":"Seront","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Coulie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miikka","family":"Vikkula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence M.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"4151_CR1","doi-asserted-by":"crossref","unstructured":"Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the International society for the study of vascular anomalies. Pediatrics [Internet]. 2015\/06\/10. 2015;136(1):e203\u201314. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26055853.","DOI":"10.1542\/peds.2014-3673"},{"key":"4151_CR2","volume-title":"Genetic basis and therapies for vascular anomalies","author":"A Queisser","year":"2021","unstructured":"Queisser A, Seront E, Boon LM, Vikkula M. Genetic basis and therapies for vascular anomalies. Vol. 129. Circulation Research; 2021."},{"key":"4151_CR3","doi-asserted-by":"crossref","unstructured":"Seront E, Van Damme A, Boon LM, Vikkula M. Rapamycin and treatment of venous malformations. Curr Opin Hematol [Internet]. 2019\/03\/12. 2019;26(3):185\u201392. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30855337.","DOI":"10.1097\/MOH.0000000000000498"},{"key":"4151_CR4","doi-asserted-by":"crossref","unstructured":"Van Damme A, Seront E, Dekeuleneer V, Boon LM, Vikkula M. New and emerging targeted therapies for vascular malformations. Am J Clin Dermatol [Internet]. 2020\/06\/20. 2020;21(5):657\u201368. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32557381.","DOI":"10.1007\/s40257-020-00528-w"},{"key":"4151_CR5","doi-asserted-by":"crossref","unstructured":"Dekeuleneer V, Seront E, Van Damme A, Boon LM, Vikkula M. Theranostic advances in vascular malformations. J Invest Dermatol. 2020;140.","DOI":"10.1016\/j.jid.2019.10.001"},{"key":"4151_CR6","doi-asserted-by":"crossref","unstructured":"Boscolo E, Limaye N, Huang L, Kang KT, Soblet J, Uebelhoer M, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Investigation. 2015;125(9).","DOI":"10.1172\/JCI76004"},{"issue":"5","key":"4151_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1161\/ATVBAHA.118.310760","volume":"38","author":"E Alsina-Sanch\u00eds","year":"2018","unstructured":"Alsina-Sanch\u00eds E, Garc\u00eda-Ib\u00e1\u00f1ez Y, Figueiredo AM, Riera-Domingo C, Figueras A, Matias-Guiu X, et al. ALK1 loss results in vascular hyperplasia in mice and humans through PI3K activation. Arterioscler Thromb Vasc Biol. 2018, May;38(5):1216\u201329.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4151_CR8","doi-asserted-by":"crossref","unstructured":"Seront E, Van Damme A, Legrand C, Bisdorff-Bresson A, Orcel P, Funck-Brentano T, et al. Preliminary results of the European multicentric phase iii trial regarding sirolimus in slow-flow vascular malformations. JCI Insight. 2023;8(21).","DOI":"10.1172\/jci.insight.173095"},{"key":"4151_CR9","doi-asserted-by":"crossref","unstructured":"Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, et al. Sirolimus is efficacious in treatment for extensive and\/or complex slow-flow vascular malformations: a monocentric prospective phase II study. Orphanet J Rare Dis. 2018;13(1).","DOI":"10.1186\/s13023-018-0934-z"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04151-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04151-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:43:27Z","timestamp":1771321407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04151-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04151-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7108000\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The VASE trial was conducted in accordance with the Declaration of Helsinki and approved by Cliniques universitaires Saint-Luc ethics committees; informed consent from patients was obtained at enrollment for treatment and data collection, as well for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and approval"}},{"value":"Emmanuel Seront and Laurence Boon are the principal investigators of the VASE trial NCT02638389 and EudraCT 2015-001703-32, An Van Damme, Julien Coulie and Miikka Vikkula have no conflict of interest exists.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"62"}}